Clinical trials: Double-blind Design
Primary Hypercholesterolemia
Efficacy and Safety of Combination of Rosuvastatin and Ezetimibe in Patients With Primary Hypercholesterolemia
The purpose of this study is to evaluate efficacy and safety of HL140 in patients with primary hypercholesterolemia.
- Trial name
- NCT03571087
- Testing
- HL140 5/10, HL140 10/10, HL140 20/10
- Volunteers
- 374 people
- Sponsor
- Hanlim Pharm. Co., Ltd.
Actinic Keratosis
A Study Comparing Diclofenac Sodium Gel 3% to Solaraze® (Diclofenac Sodium) Gel 3% in the Treatment of Actinic Keratosis
To compare the relative efficacy and safety of the test formulation diclofenac sodium gel 3% (Actavis) to the marketed formulation Solaraze® (diclofenac sodium) Gel 3% (Fougera Pharms) in the treatment of the actinic keratosis
- Trial name
- NCT01962987
- Testing
- Diclofenac sodium
- Where
- 31 sites in United States
- Volunteers
- 476 people
- Sponsor
- Actavis Inc.
Bronchial Asthma
Efficacy and Tolerability of Beclomethasone Dipropionate 100 µg + Formoterol 6 µg pMDI Via HFA-134a Vs. Budesonide 160 µg + Formoterol 4,5 µg Dry Powder Via Turbuhaler®. (Symbicort®)
The aim of this study was to compare the efficacy and tolerability of the fixed combination beclomethasone/formoterol pMDI with that of budesonide/formoterol dry powder via Turbuhaler.
- Trial name
- NCT00413387
- Testing
- beclomethasone dipropionate plus formoterol fumarate combination, budesonide plus formoterol combination
- Where
- 13 sites in Austria, Poland and 1 more
- Volunteers
- 219 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Idiopathic Pulmonary Fibrosis (IPF)
A Adaptive Design Clinical Trial to Evaluate the Efficacy and Safety of TDI01 Suspension in the Treatment of Idiopathic Pulmonary Fibrosis (IPF)
This study is a multicentre, randomised, double-blind, placebo-controlled, adaptive design clinical trial to evaluate the efficacy and safety of TDI01 suspension in the treatment of idiopathic pulmonary fibrosis (IPF).
- Trial name
- NCT07464912
- Testing
- TDI01
- Where
- China
- Volunteers
- 508 people
- Sponsor
- Beijing Tide Pharmaceutical Co., Ltd
Healthy
A Study to Assess the Cardiac Safety of Oritavancin in Healthy Participants
The purpose of the study was to generate cardiac safety data using a supratherapeutic oritavancin dose of 1600 milligrams (mg).
- Trial name
- NCT01762839
- Testing
- Single-Dose IV Oritavancin Diphosphate, Moxifloxacin
- Where
- United States
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Melinta Therapeutics, Inc.
Non Segmental Vitiligo
ICP-332 in Subjects With Non-segmental Vitiligo
This a phase II/III randomized, double-blind, placebo-controlled, parallel group, adaptive design, multi-center study to evaluate the efficacy and safety of ICP-332 in subjects with non-segmental vitiligo。The study consisted an…
- Trial name
- NCT07047612
- Testing
- ICP-332 Tablets
- Where
- 45 sites in China
- Volunteers
- 603 people
- Sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.
Irritable Bowel Syndrome With Diarrhea
Clinical Study to Evaluate the IBS Symptoms Improving Effect and Safety of GTB1
This study was conducted to investigate the effects of daily supplementation of L. plantarum APsulloc 331261(GTB1TM) on improvement of IBS symptoms.
- Trial name
- NCT05277428
- Testing
- GTB1
- Where
- South Korea
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Amorepacific Corporation
Migraine
Post-marketing Clinical Trial of Elexir(Trigeminal Nerve Electrical Stimulator) for the Acute Treatment of Migraine
The purpose of this study is to evaluate the efficacy and safety of treating migraine in the acute phase by applying the acute mode (program 1) of Elexir (trigeminal nerve electrical stimulator) to patients with migraine.
- Trial name
- NCT06170411
- Testing
- Elexir (program1)
- Where
- 2 sites in South Korea
- Volunteers
- 100 people
- Sponsor
- Nu Eyne Co., Ltd.
Healthy
21 Day Irritancy Test of Azelaic Acid Pre-foam Formulation
The purpose of this study is to determine the irritancy potential of azelaic acid pre-foam formulation.
- Trial name
- NCT01430312
- Testing
- azelaic acid pre-foam formulation, Vehicle pre-foam formulation, Water
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- LEO Pharma
Benign Prostatic Hyperplasia
Study of Tadalafil Once-a Day for 12 Weeks in Men With Signs and Symptoms of Benign Prostatic Hyperplasia
This is a randomized, double-blind, placebo-controlled, parallel-design, multinational, 12-week study to compare the efficacy, dose response, and safety of tadalafil once a day versus placebo in men with signs and symptoms of…
- Trial name
- NCT00384930
- Testing
- tadalafil
- Where
- United States
- Volunteers
- 1,058 people
- Sponsor
- Eli Lilly and Company
COVID-19
Phase III Trial of A COVID-19 Vaccine of Adenovirus Vector in Adults 18 Years Old and Above
This study is a global multicenter, randomized, double-blind, placebo -controlled, adaptive designed phase Ⅲ clinical trial, in order to evaluate the efficacy, safety and immunogenicity of Recombinant Novel Coronavirus Vaccine…
- Trial name
- NCT04526990
- Testing
- Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)
- Where
- 74 sites in Argentina, Chile and 3 more
- Volunteers
- 44,247 people, healthy volunteers welcome
- Sponsor
- CanSino Biologics Inc.
Covid19
Fluvoxamine Administration in Moderate SARS-CoV-2 (COVID-19) Infected Patients
This is a randomized, double-blind, placebo-controlled, adaptive two-stage design, human phase 2 study, with add-on treatment arrangement of fluvoxamine or placebo on top of standard of care (base therapy: the actual proposed…
- Trial name
- NCT04718480
- Testing
- Fluvoxamine
- Where
- 4 sites in Hungary
- Volunteers
- 66 people
- Sponsor
- SigmaDrugs Research Ltd.
Primary Hypercholesterolemia, Mixed Dyslipidemia
Efficacy and Safety of Extended-Release Niacin/ Laropiprant/Simvastatin Tablets in Participants With Hypercholesterolemia or Mixed Dyslipidemia (MK-0524B-143)
This study is being done to find out if tablets containing extended release (ER) niacin, laropiprant, and simvastatin (ERN/LRPT/SIM) are as effective as tablets containing ER niacin and laropiprant taken with simvastatin tablets…
- Trial name
- NCT01335997
- Testing
- ER niacin/laropiprant (ERN/LRPT), ER niacin/laropiprant/simvastatin (ERN/LRPT/SIM), Simvastatin (SIM)
- Volunteers
- 1,139 people
- Sponsor
- Merck Sharp & Dohme LLC
Dyspareunia
Study Comparing Estradiol Vaginal Inserts 4mcg To IMVEXXY ® (Estradiol Vaginal Inerts 4 mcg) In The Treatment Of Dyspareunia in Women With Vulvur and Vaginal Atrophy
Randomized, double-blind, placebo-controlled, parallel-designed, multiple-site, bioequivalence study with clinical endpoints.
- Trial name
- NCT05617820
- Testing
- Estradiol, Imvexxy
- Where
- 48 sites in United States, El Salvador and 1 more
- Volunteers
- 1,050 people, healthy volunteers welcome
- Sponsor
- Teva Pharmaceuticals USA
Urinary Catheter Blockage and Encrustation
Study to Evaluate NVC-422 for Urinary Catheter Blockage and Encrustation
NVC-422 is a topical, non-antibiotic, fast-acting, broad-spectrum anti-microbial, which exhibits the potential to prevent the growth of urinary pathogens, including Proteus and others.
- Trial name
- NCT01243125
- Testing
- NVC-422, 0.2%, Sterile normal saline, 0.9%
- Where
- 8 sites in United States
- Volunteers
- 67 people
- Sponsor
- NovaBay Pharmaceuticals, Inc.
Osteoporosis, Postmenopausal
Multicenter Study in Postmenopausal Women With Osteoporosis, ALVOBOND
This is a randomized, double-blind, parallel design, repeat dose, 2 arm, multicenter study comparing the efficacy, safety, immunogenicity, pharmacodynamic (PD) and pharmacokinetic (PK) profiles of AVT03 and US-Prolia in…
- Trial name
- ALVOBOND (NCT05395091)
- Testing
- AVT03, Denosumab
- Where
- 34 sites in Bulgaria, Czechia and 3 more
- Volunteers
- 532 people
- Sponsor
- Alvotech Swiss AG
Vaginosis, Bacterial
Safety, Tolerability and Efficacy of Vaginal Suppository WO3191 in the Post-treatment of Bacterial Vaginosis
Bacterial Vaginosis (BV) is a common infectious disorder and is characterized by a disturbance in the vaginal microbiological milieu.
- Trial name
- NCT02687789
- Testing
- Medical Device: WO3191, Medical Device: Vagisan® Lactic Acid
- Where
- 13 sites in Germany
- Volunteers
- 43 people
- Sponsor
- Dr. August Wolff GmbH & Co. KG Arzneimittel
COVID-19
Efficacy and Safety of hzVSF-v13 in Moderate to Severe Patients With COVID-19 Pneumonia
Explore the efficacy and confirm the safety of the concomitant administration of the standard of care and hzVSF-v13 in patients with COVID-19 infection
- Trial name
- NCT04679415
- Testing
- hzVSF-v13
- Where
- 3 sites in Indonesia
- Volunteers
- 63 people
- Sponsor
- ImmuneMed, Inc.
Alzheimer's Disease, Dementia
Safety and Efficacy Study of Ladostigil in Mild to Moderate Probable Alzheimer's Disease
For many, Alzheimer's disease is the number one medical issue facing our aging society. It is a late onset neurodegenerative disease, frequently under diagnosed, that impairs memory and cognitive performance.
- Conditions
- Alzheimer's Disease, Dementia, Memory Loss, Cognitive Impairment
- Trial name
- NCT01354691
- Testing
- ladostigil hemitartrate
- Where
- 19 sites in Austria, Croatia and 3 more
- Volunteers
- 200 people
- Sponsor
- Avraham Pharmaceuticals Ltd
Bronchial Asthma
EFFICACY AND TOLERABILITY OF BECLOMETHASONE DIPROPIONATE 100 µg + FORMOTEROL 6 µg pMDI VIA HFA-134a vs. FLUTICASONE 125 µg + SALMETEROL 25 µg pMDI
The aim of this study was to compare the efficacy and tolerability of the fixed combination beclomethasone/formoterol pMDI with that of fluticasone/salmeterol pMDI in patients with moderate to severe asthma
- Trial name
- NCT00394368
- Testing
- beclomethasone dipropionate plus formoterol fumarate combination, fluticasone propionate plus salmeterol xinafoate combination
- Where
- 12 sites in Poland, Ukraine
- Volunteers
- 180 people
- Sponsor
- Chiesi Farmaceutici S.p.A.